Neoadjuvant Osimertinib With/Without Chemotherapy Versus Chemotherapy Alone for EGFR-Mutated Resectable Non-Small-Cell Lung Cancer: NeoADAURA

References

• Le Chevalier T . Adjuvant chemotherapy for resectable non-small-cell lung cancer: where is it going?Ann. Oncol.21(Suppl. 7), vii196–198 (2010).
   PubMedGoogle Scholar
• Datta D , LahiriB. Preoperative evaluation of patients undergoing lung resection surgery. Chest123(6), 2096–2103 (2003).
   PubMed Web of Science ®Google Scholar
• Cagle PT , AllenTC, OlsenRJ. Lung cancer biomarkers: present status and future developments. Arch. Pathol. Lab. Med.137(9), 1191–1198 (2013).
   PubMed Web of Science ®Google Scholar
• Postmus PE , KerrKM, OudkerkMet al. Early-stage and locally advanced (non-metastatic) non-small-cell lung cancer: ESMO Clinical Practice Guidelines. Ann. Oncol.28(Suppl. 4), iv1–iv21 (2017).
   PubMedGoogle Scholar
• Goldstraw P , ChanskyK, CrowleyJet al. The IASLC Lung Cancer Staging Project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J. Thorac. Oncol.11(1), 39–51 (2016).
   PubMed Web of Science ®Google Scholar
• Zhou X , CaiL, LiuJet al. Analyzing EGFR mutations and their association with clinicopathological characteristics and prognosis of patients with lung adenocarcinoma. Oncol. Lett.16(1), 362–370 (2018).
   PubMed Web of Science ®Google Scholar
• Zhang Z , WangT, ZhangJet al. Prognostic value of epidermal growth factor receptor mutations in resected non-small-cell lung cancer: a systematic review with meta-analysis. PLoS ONE9(8), e106053 (2014).
   PubMed Web of Science ®Google Scholar
• Zhao Y , WangW, LiangHet al. The optimal treatment for stage IIIA-N2 non-small-cell lung cancer: a network meta-analysis. Ann. Thorac. Surg.107(6), 1866–1875 (2019).
   PubMed Web of Science ®Google Scholar
• Albain KS , SwannRS, RuschVWet al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a Phase III randomised controlled trial. Lancet374(9687), 379–386 (2009).
   PubMed Web of Science ®Google Scholar
• Zhong WZ , WangQ, MaoWMet al. Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II–IIIA (N1-N2) EGFR-mutant NSCLC: final overall survival analysis of CTONG1104 Phase III trial. J. Clin. Oncol.39(7), 713–722 (2021).
   PubMed Web of Science ®Google Scholar
• Zhai H , ZhongW, YangX, WuYL. Neoadjuvant and adjuvant epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) therapy for lung cancer. Transl. Lung Cancer Res.4(1), 82–93 (2015).
   PubMedGoogle Scholar
• Hellmann MD , ChaftJE, WilliamWNJret al. Pathological response after neoadjuvant chemotherapy in resectable non-small-cell lung cancers: proposal for the use of major pathological response as a surrogate endpoint. Lancet Oncol.15(1), e42–50 (2014).
   PubMed Web of Science ®Google Scholar
• NSCLC Meta-analysis Collaborative Group . Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data. Lancet383(9928), 1561–1571 (2014).
   PubMed Web of Science ®Google Scholar
• Burdett S , StewartLA, RydzewskaL. A systematic review and meta-analysis of the literature: chemotherapy and surgery versus surgery alone in non-small-cell lung cancer. J. Thorac. Oncol.1(7), 611–621 (2006).
   PubMed Web of Science ®Google Scholar
• Brunelli A , RoccoG, SzantoZ, ThomasP, FalcozPE. Morbidity and mortality of lobectomy or pneumonectomy after neoadjuvant treatment: an analysis from the ESTS database. Eur. J. Cardiothorac. Surg.57(4), 740–746 (2020).
   PubMed Web of Science ®Google Scholar
• Planchard D , PopatS, KerrKet al. Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. ESMO Guidelines Committee (2020). https://www.esmo.org/guidelines/lung-and-chest-tumours/clinical-practice-living-guidelines-metastatic-non-small-cell-lung-cancer
   Google Scholar
• Wu YL , TsuboiM, HeJet al. Osimertinib in resected EGFR-mutated non-small-cell lung cancer. N. Engl. J. Med.383(18), 1711–1723 (2020).
   PubMed Web of Science ®Google Scholar
• Lv C , MaY, FengQet al. Does neoadjuvant targeted therapy provide an opportunity for resectable EGFR-mutant lung cancer: a real-world retrospective study. J. Thorac. Dis.12(10), 5324–5335 (2020).
   PubMed Web of Science ®Google Scholar
• Zhong WZ , ChenKN, ChenCet al. Erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small-cell lung cancer (EMERGING-CTONG 1103): a randomized Phase II study. J. Clin. Oncol.37(25), 2235–2245 (2019).
   PubMed Web of Science ®Google Scholar
• Xiong L , LiR, SunJet al. Erlotinib as neoadjuvant therapy in stage IIIA (N2) EGFR mutation-positive non-small-cell lung cancer: a prospective, single-arm, Phase II study. Oncologist24(2), 157–e164 (2019).
   PubMed Web of Science ®Google Scholar
• Xiong L , LouY, BaiHet al. Efficacy of erlotinib as neoadjuvant regimen in EGFR-mutant locally advanced non-small-cell lung cancer patients. J. Int. Med. Res.48(4), https://doi.org/10.1177/0300060519887275 (2020).
   Google Scholar
• Zhong W , YangX, YanHet al. Phase II study of biomarker-guided neoadjuvant treatment strategy for IIIA-N2 non-small-cell lung cancer based on epidermal growth factor receptor mutation status. J. Hematol. Oncol.8, 54 (2015).
   PubMed Web of Science ®Google Scholar
• Zhang Y , FuF, HuHet al. Gefitinib as neoadjuvant therapy for resectable stage II–IIIA non-small-cell lung cancer: a Phase II study. J. Thorac. Cardiovasc. Surg.doi:10.1016/j.jtcvs.2020.02.131 (2020).
   Web of Science ®Google Scholar
• Hosomi Y , MoritaS, SugawaraSet al. Gefitinib alone versus gefitinib plus chemotherapy for non-small-cell lung cancer with mutated epidermal growth factor receptor: NEJ009 study. J. Clin. Oncol.38(2), 115–123 (2020).
   PubMed Web of Science ®Google Scholar
• Noronha V , PatilVM, JoshiAet al. Gefitinib versus gefitinib plus pemetrexed and carboplatin chemotherapy in EGFR-mutated lung cancer. J. Clin. Oncol.38(2), 124–136 (2020).
   PubMed Web of Science ®Google Scholar
• Cross DA , AshtonSE, GhiorghiuSet al. AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov.4(9), 1046–1061 (2014).
   PubMed Web of Science ®Google Scholar
• Mok TS , WuY-L, AhnM-Jet al. Osimertinib or platinum–pemetrexed in EGFR T790M–positive lung cancer. N. Engl. J. Med.376(7), 629–640 (2017).
   PubMed Web of Science ®Google Scholar
• Soria JC , OheY, VansteenkisteJet al. Osimertinib in untreated EGFR-mutated advanced non-small-cell lung cancer. N. Engl. J. Med.378(2), 113–125 (2018).
   PubMed Web of Science ®Google Scholar
• Wu YL , AhnMJ, GarassinoMCet al. CNS efficacy of osimertinib in patients with T790M-positive advanced non-small-cell lung cancer: data from a randomized Phase III trial (AURA3). J. Clin. Oncol.36(26), 2702–2709 (2018).
   PubMed Web of Science ®Google Scholar
• Reungwetwattana T , NakagawaK, ChoBCet al. CNS response to osimertinib versus standard epidermal growth factor receptor tyrosine kinase inhibitors in patients with untreated EGFR-mutated advanced non-small-cell lung cancer. J. Clin. Oncol.36, 3290–3297 (2018).
   Web of Science ®Google Scholar
• Ramalingam SS , VansteenkisteJ, PlanchardDet al. Overall survival with osimertinib in untreated, EGFR-mutated advanced NSCLC. N. Engl. J. Med.382(1), 41–50 (2020).
   PubMed Web of Science ®Google Scholar
• Papadimitrakopoulou VA , MokTS, HanJYet al. Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis. Ann. Oncol.31(11), 1536–1544 (2020).
   PubMed Web of Science ®Google Scholar
• U.S. Food and Drug Administration . TAGRISSO® Highlights of Prescribing Information. (2018). https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/208065s008lbl.pdf
   Google Scholar
• European Medicines Agency . Tagrisso, INN-osimertinib. (2016). https://www.ema.europa.eu/en/documents/product-information/tagrisso-epar-product-information_en.pdf
   Google Scholar
• US Food and Drug Administration . FDA approves osimertinib as adjuvant therapy for non-small-cell lung cancer with EGFR mutations. (2020). https://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-osimertinib-adjuvant-therapy-non-small-cell-lung-cancer-egfr-mutations#:∼:text=On%20December%2018%2C%202020%2C%20the,exon%2021%20L858R%20mutations%2C%20as
   Google Scholar
• Rotow J , UrismanA, MccoachCet al. P1.14-58 A phase II study to evaluate neoadjuvant osimertinib for surgically resectable, EGFR-mutant non-small-cell lung cancer. J. Thorac. Oncol.14(10), S578 (2019).
   Web of Science ®Google Scholar
• IASLC Staging Manual in Thoracic Oncology. 2nd Edition. Editorial Rx Press, North Fort Myers, FL, USA (2016).
   Google Scholar
• AJCC Cancer Staging Manual. 8th Edition. Springer International Publishing (2017).
   Google Scholar
• AJCC Cancer Staging Handbook. 7th Edition. Springer, London, UK (2010).
   Google Scholar
• Pisters KMW , VallièresE, CrowleyJJet al. Surgery with or without preoperative paclitaxel and carboplatin in early-stage non–small-cell lung cancer: Southwest Oncology Group Trial S9900, an intergroup, randomized, Phase III trial. J. Clin. Oncol.28(11), 1843–1849 (2010).
   PubMed Web of Science ®Google Scholar
• Betticher DC , HsuSchmitz SF, TotschMet al. Prognostic factors affecting long-term outcomes in patients with resected stage IIIA pN2 non-small-cell lung cancer: 5-year follow-up of a Phase II study. Br. J. Cancer94(8), 1099–1106 (2006).
   PubMed Web of Science ®Google Scholar
• Westeel V , QuoixE, PuyraveauMet al. A randomised trial comparing preoperative to perioperative chemotherapy in early-stage non-small-cell lung cancer (IFCT 0002 trial). Eur. J. Cancer49(12), 2654–2664 (2013).
   PubMed Web of Science ®Google Scholar
• Chaft JE , OxnardGR, SimaCS, KrisMG, MillerVA, RielyGJ. Disease flare after tyrosine kinase inhibitor discontinuation in patients with EGFR-mutant lung cancer and acquired resistance to erlotinib or gefitinib: implications for clinical trial design. Clin. Cancer Res.17(19), 6298–6303 (2011).
   PubMed Web of Science ®Google Scholar
• Zhang YL , YuanJQ, WangKFet al. The prevalence of EGFR mutation in patients with non-small-cell lung cancer: a systematic review and meta-analysis. Oncotarget7(48), 78985–78993 (2016).
   PubMedGoogle Scholar
• Blumenthal GM , BunnPAJr, ChaftJEet al. Current status and future perspectives on neoadjuvant therapy in lung cancer. J. Thorac. Oncol.13(12), 1818–1831 (2018).
   PubMed Web of Science ®Google Scholar
• Pataer A , KalhorN, CorreaAMet al. Histopathologic response criteria predict survival of patients with resected lung cancer after neoadjuvant chemotherapy. J. Thorac. Oncol.7(5), 825–832 (2012).
   PubMed Web of Science ®Google Scholar
• Cascone T , GoldKA, SwisherSGet al. Induction cisplatin docetaxel followed by surgery and erlotinib in non-small-cell lung cancer. Ann. Thorac. Surg.105(2), 418–424 (2018).
   PubMed Web of Science ®Google Scholar
• Weissferdt A , PataerA, VaporciyanAAet al. Agreement on major pathological response in NSCLC patients receiving neoadjuvant chemotherapy. Clin. Lung Cancer21(4), 341–348 (2020).
   PubMed Web of Science ®Google Scholar
• Melek H , ÇetinkayaG, ÖzerEet al. Pathological complete response after neoadjuvant/induction treatment: where is its place in the lung cancer staging system?†. Eur. J. Cardiothorac. Surg.56(3), 604–611 (2019).
   PubMed Web of Science ®Google Scholar
• Ren S , WangC, ShenJ, ZhuC. Neoadjuvant immunotherapy with resectable non-small-cell lung cancer: recent advances and future challenges. J. Thorac. Dis.12(4), 1615–1620 (2020).
   PubMed Web of Science ®Google Scholar
• Proto C , FerraraR, SignorelliDet al. Choosing wisely first line immunotherapy in non-small-cell lung cancer (NSCLC): what to add and what to leave out. Cancer Treat. Rev.75, 39–51 (2019).
   PubMed Web of Science ®Google Scholar
• Bruno D , DowlatiA. Immunotherapy in EGFR mutant non-small-cell lung cancer: when, who and how?Transl. Lung Cancer Res.8(5), 710–714 (2019).
   PubMed Web of Science ®Google Scholar